About Hindustan Bio Sciences Limited
Data last updated:
Hindustan Bio Sciences Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 December 1991 and has been in existence for over 35 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L26942TG1991PLC013564. Its GSTIN is 36AABCG3236A1Z8 (Telangana). The company holds 2 GST registrations, of which 1 is active. Its shares are listed on BSE: 532041.
The company has an authorised share capital of ₹11 Cr and a paid-up capital of ₹2.05 Cr. It is led by directors including Venkata Rama Mohan Raju Jampana (Managing Director) and Uma Jampana.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No.31 Sagar Society Road No.2 Banjarahills, Hyderabad, Telangana, India – 500034.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹74 Lakh, a decline of 8.6% compared to the previous year. For the same year it recorded a net loss of ₹8 Lakh (net margin -10.8%) and EBITDA of -₹6 Lakh (EBITDA margin -8.1%). The net worth stands at ₹83 Lakh (down 7.8% YoY). Total assets are valued at ₹3.18 Cr (down 6.7% YoY).
The company is associated with 1 brand: Hindustan Bio Sciences Limited. As per MCA filings, the company has open charges of ₹7.5 Cr and satisfied charges of ₹14.7 Lakh on record. Court records list 5 cases involving the company, including 1 filed by the company and 4 filed against it. The company has 78 deals on record (78 market trades); the latest was in October 2025. The company has 1 MSME Form 1 return on record for the period ending Jan 2019, listing 1 overdue payment to 1 micro and small supplier.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hindustanbiosciences.in.
CIN History
Hindustan Bio Sciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L26942TG1991PLC013564, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L26942TG1991PLC013564 | Current |
| U26942AP1991PLC013564 | Previous |
| L26942AP1991PLC013564 | Previous |
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressPlot No.31 Sagar Society Road No.2 Banjarahills, Hyderabad, Telangana, India – 500034
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Associated Brands
Hindustan Bio Sciences operates one associated brand: Hindustan Bio Sciences Limited. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Hindustan Bio Sciences Limited is engaged in pharmaceutical and biotechnology operations. | hindustanbiosciences.in |
Business Activity
The main business activity of Hindustan Bio Sciences is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Financials of Hindustan Bio Sciences Limited
FY 2025-26 filings availableHindustan Bio Sciences Limited reported revenue of ₹74 Lakh (down 8.6% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.74 | 0.81 | 1.05 | 0.92 | 0.43 | 1.03 | 1.94 |
| Revenue growth | -8.6% | -22.9% | +14.1% | +114.0% | -58.3% | -46.9% | - |
| EBITDA | (0.06) | 0.10 | 0.06 | (0.03) | (0.50) | (0.95) | 0.13 |
| EBITDA margin | -8.1% | +12.4% | +5.7% | -3.3% | -116.3% | -92.2% | +6.7% |
| Profit before tax | (0.08) | 0.10 | 0.05 | (0.04) | (0.50) | (0.97) | 0.11 |
| Net profit | (0.08) | 0.10 | 0.05 | (0.04) | (0.50) | (0.95) | 0.07 |
| Net profit margin | -10.8% | +12.4% | +4.8% | -4.4% | -116.3% | -92.2% | +3.6% |
| EPS (₹) | (0.08) | 0.10 | 0.06 | (0.20) | (0.50) | (0.92) | 0.08 |
| Balance sheet | |||||||
| Total assets | 3.18 | 3.41 | 3.36 | 3.20 | 2.95 | 3.16 | 4.84 |
| Net worth | 0.83 | 0.90 | 0.80 | 0.75 | 0.79 | 1.30 | 2.24 |
| Total debt | 2.35 | 2.51 | 2.56 | 2.46 | 2.17 | 1.86 | 2.60 |
| Cash & bank | 0.13 | 0.01 | 0.04 | 0.01 | 0.01 | 0.02 | 0.20 |
| Net working capital | 0.75 | 0.98 | 0.94 | 0.76 | 0.53 | 0.73 | 1.59 |
| Cash flow | |||||||
| Cash from operations | 0.28 | 0.03 | (1.41) | (0.05) | (0.34) | 0.75 | 0.82 |
| Cash from investing | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from financing | (0.16) | (0.05) | 1.43 | 0.05 | 0.34 | (0.93) | (0.81) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.38 | 0.00 | 0.32 | 0.38 | 0.00 | 0.41 |
| Revenue growth (YoY) | -100.0% | -100.0% | - | -100.0% | -22.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 |
| Total expenses | 0.11 | 0.11 | 0.31 | 0.06 | 0.32 | 0.28 | 0.04 | 0.34 |
| EBITDA | (0.11) | (0.11) | 0.07 | (0.06) | 0.00 | 0.10 | (0.04) | 0.07 |
| EBITDA margin | - | - | +18.4% | - | 0.0% | +26.3% | - | +17.1% |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.11) | (0.11) | 0.08 | (0.05) | 0.01 | 0.11 | (0.04) | 0.08 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.38 | 0.00 | 0.32 | 0.38 | 0.00 | 0.41 |
| Revenue growth (YoY) | -100.0% | -100.0% | - | -100.0% | -22.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 |
| Total expenses | 0.11 | 0.11 | 0.31 | 0.06 | 0.32 | 0.28 | 0.04 | 0.34 |
| EBITDA | (0.11) | (0.11) | 0.07 | (0.06) | 0.00 | 0.10 | (0.04) | 0.07 |
| EBITDA margin | - | - | +18.4% | - | 0.0% | +26.3% | - | +17.1% |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.11) | (0.11) | 0.08 | (0.05) | 0.01 | 0.11 | (0.04) | 0.08 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.74 | 0.81 | 1.05 | 0.92 | 0.43 | 1.03 | 1.94 |
| Revenue growth | -8.6% | -22.9% | +14.1% | +114.0% | -58.3% | -46.9% | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.80 | 0.71 | 0.99 | 0.95 | 0.93 | 1.98 | 1.81 |
| Employee cost | 0.00 | 0.07 | 0.09 | 0.18 | 0.18 | 0.19 | 0.20 |
| EBITDA | (0.06) | 0.10 | 0.06 | (0.03) | (0.50) | (0.95) | 0.13 |
| EBITDA margin | -8.1% | +12.4% | +5.7% | -3.3% | -116.3% | -92.2% | +6.7% |
| Depreciation | 0.02 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Profit before tax | (0.08) | 0.10 | 0.05 | (0.04) | (0.50) | (0.97) | 0.11 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | 0.04 |
| Net profit | (0.08) | 0.10 | 0.05 | (0.04) | (0.50) | (0.95) | 0.07 |
| Net profit margin | -10.8% | +12.4% | +4.8% | -4.4% | -116.3% | -92.2% | +3.6% |
| EPS (₹) | (0.08) | 0.10 | 0.06 | (0.20) | (0.50) | (0.92) | 0.08 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 2.05 | 2.05 | 2.05 | 2.05 | 10.25 | 10.25 | 10.25 |
| Reserves & surplus | (1.22) | (1.15) | (1.25) | (1.30) | (9.46) | (8.95) | (8.01) |
| Shareholders' funds (net worth) | 0.83 | 0.90 | 0.80 | 0.75 | 0.79 | 1.30 | 2.24 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 2.35 | 2.51 | 2.56 | 2.46 | 2.17 | 1.86 | 2.60 |
| Total debt | 2.35 | 2.51 | 2.56 | 2.46 | 2.17 | 1.86 | 2.60 |
| Total liabilities | 3.18 | 3.41 | 3.36 | 3.20 | 2.95 | 3.16 | 4.84 |
| Assets | |||||||
| Gross block | 0.27 | 0.55 | 0.55 | 0.55 | 0.55 | 0.54 | 0.54 |
| Net block | 0.01 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 |
| Sundry debtors | 0.05 | 0.44 | 0.44 | 0.45 | 0.14 | 0.62 | 1.36 |
| Cash & bank balances | 0.13 | 0.01 | 0.04 | 0.01 | 0.01 | 0.02 | 0.20 |
| Loans & advances | 0.59 | 0.54 | 0.47 | 0.39 | 0.40 | 0.41 | 0.41 |
| Total current assets | 0.77 | 0.99 | 0.95 | 0.85 | 0.55 | 1.05 | 2.31 |
| Total current liabilities | 0.02 | 0.01 | 0.01 | 0.09 | 0.02 | 0.32 | 0.72 |
| Net working capital | 0.75 | 0.98 | 0.94 | 0.76 | 0.53 | 0.73 | 1.59 |
| Total assets | 3.18 | 3.41 | 3.36 | 3.20 | 2.95 | 3.16 | 4.84 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.01 | 0.04 | 0.01 | 0.01 | 0.02 | 0.20 | 0.18 |
| Net cash from operating activities | 0.28 | 0.03 | (1.41) | (0.05) | (0.34) | 0.75 | 0.82 |
| Net cash from investing activities | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net cash from financing activities | (0.16) | (0.05) | 1.43 | 0.05 | 0.34 | (0.93) | (0.81) |
| Net change in cash | 0.12 | (0.02) | 0.03 | 0.00 | (0.01) | (0.18) | 0.01 |
| Closing cash | 0.13 | 0.01 | 0.04 | 0.01 | 0.01 | 0.02 | 0.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -8.6% | -22.9% | +14.1% | +114.0% | -58.3% | -46.9% | - |
| EBITDA growth | -160.0% | +66.7% | +300.0% | +94.0% | +47.4% | -830.8% | - |
| PBT growth | - | +100.0% | +9998.0% | +92.0% | +48.5% | - | +10.0% |
| Net income growth | -180.0% | +100.0% | +225.0% | +92.0% | +47.4% | -1457.1% | - |
| Revenue CAGR (3Y) | -7.0% | +23.5% | +0.6% | -22.0% | -50.6% | 0.0% | +24.3% |
| EBITDA CAGR (3Y) | +26.0% | - | - | - | - | -26.1% | - |
| Profitability & leverage | |||||||
| Net income margin | -10.8% | +12.4% | +4.8% | -4.4% | -116.3% | -92.2% | +3.6% |
| Return on capital employed | - | +2.2% | +1.5% | 0.0% | 0.0% | 0.0% | +1.0% |
| Return on net worth | - | +4.9% | +4.3% | 0.0% | 0.0% | 0.0% | +0.8% |
| Debt / equity | - | 2.98 | 3.24 | 3.01 | 1.93 | 1.26 | 1.36 |
| Long-term debt / equity | - | 2.98 | 2.38 | 1.43 | 0.87 | 0.68 | 0.94 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.04 | 8.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.47 | 1.91 | 1.67 | 0.79 | 1.91 | 3.59 |
| Inventory turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 6.06 | 8.62 |
| Debtors turnover | - | 1.84 | 2.36 | 3.12 | 1.13 | 1.04 | 1.28 |
| EPS (₹) | (0.08) | 0.10 | 0.06 | (0.20) | (0.50) | (0.92) | 0.08 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 0.88 | 0.78 | 3.64 | 0.77 | 1.27 | 2.19 |
Board of Directors of Hindustan Bio Sciences Limited
Hindustan Bio Sciences has 6 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Uma Jampana Also directs: Super Solutions (India)Private Limited, Aiwon Life Sciences LLP | Director | 30 Oct 2007 | 18 Years 11 Months | Current |
| Venkata Rama Mohan Raju Jampana | Managing Director | 10 Jun 2000 | 26 Years 4 Months | Current |
| Nagi Reddy Bodeddula Also directs: Muttonly Farms Private Limited, Sendcrux Labs Private Limited | Director | 30 Sep 2024 | 2 Years 0 Months | Current |
| Pratheek Reddy Gorrela | Director | 30 Sep 2024 | 2 Years 0 Months | Current |
| Jaison George | Director | 31 Oct 2023 | 2 Years 11 Months | Current |
| Reji Abraham Also directs: Harvey Laboratories Private Limited | Director | 31 Oct 2023 | 2 Years 11 Months | Current |
Auditor Details
Hindustan Bio Sciences Limited is audited by VASG & Associates for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| VASG & Associates | Locked | Locked | Locked |
: available in the company report
Shareholding Pattern
Shareholding for the quarter ended Mar 2026: promoters hold 12.20%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 87.80%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 12.20% | 12.20% | 12.20% | 12.20% |
| Public | 87.80% | 87.80% | 87.80% | 87.80% |
Charges & Borrowings
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Sep 1994 | Andhra Pradesh State Financial Corporation | ₹14.7 Lakh | Satisfied |
Total charge records: 1 View all charges
Deals & Funding
Hindustan Bio Sciences Limited has 78 deals on record (78 market trades); the latest was in October 2025.
Deals on record (5 of 78)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2024 | Market trade | ₹11.3 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited , an individual Seller: Multiplier Share and Stock Advisors Private Limited |
| Oct 2024 | Market trade | ₹5.9 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited |
| Oct 2023 | Market trade | ₹9 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited |
| Oct 2023 | Market trade | ₹28.9 Lakh | Buyer: Prithvi Finmart Private Limited , Jai Vinayak Securities, BP Equities Private Limited Seller: BP Equities Private Limited , Jai Vinayak Securities, Prithvi Finmart Private Limited , an individual |
| May 2023 | Market trade | ₹46.4 Lakh | Buyer: Topgain Finance Private Limited , an individual Seller: Topgain Finance Private Limited , SVS Securities Private Limited |
: available in the company report
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases
Hindustan Bio Sciences Limited has 5 court cases on record: 1 filed by Hindustan Bio Sciences, 4 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 4 | 4 | 0 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 5)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court | Appeal | Filed against the company by Sree Venkateswara Enterprises Pvt. Ltd., | Disposed |
| High Court, ANDHRAPRADESH | Appeal | Filed against the company by Sree Venkateswara Enterprises Pvt. Ltd., | Disposed |
| High Court, ANDHRAPRADESH | Writ petition | Filed against the company by Sree Venkateswara Enterprises Pvt. Ltd., | Disposed |
| High Court | Writ petition | Filed against the company by Sree Venkateswara Enterprises Pvt. Ltd., | Disposed |
| NCLT, Hyderabad | Company petition | Filed by the company | Disposed |
: available in the company report
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays
Hindustan Bio Sciences Limited has 1 MSME Form 1 return on record for the period ending Jan 2019, listing 1 overdue payment to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (1 of 1)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| GLS Pharma Limited | •••• | •••• | •••• |
: available in the company report
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance
Employment history and EPFO contributions of people linked to Hindustan Bio Sciences.
: available in the company report
Recent Activity
Hindustan Bio Sciences Limited has 20 board changes on record since 2000: 13 appointments and 7 cessations. The latest: Nagi Reddy Bodeddula was appointed as Director on 30 Sep 2024.
13 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts
: available in the company report
Subsidiaries & Group Companies
: available in the company report
GST Compliance
Hindustan Bio Sciences has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AABCG3236A1Z8 | Telangana | Active | 01 Jul 2017 |
: available in the company report
MCA Filings & Documents
: available in the company report
Frequently Asked Questions
Hindustan Bio Sciences is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 December 1991 (35+ years old) and is registered under CIN L26942TG1991PLC013564. Listed on BSE: 532041.
Hindustan Bio Sciences reported revenue of ₹74 Lakh for FY 2025-26 (down 8.6% YoY) based on standalone financials.
Hindustan Bio Sciences has 6 current directors:
- Venkata Rama Mohan Raju Jampana - Managing Director
- Uma Jampana - Director
- Nagi Reddy Bodeddula - Director
- Pratheek Reddy Gorrela - Director
- Jaison George - Director
- Reji Abraham - Director
The latest financial statements of Hindustan Bio Sciences on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Hindustan Bio Sciences is 36AABCG3236A1Z8, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Hindustan Bio Sciences is L26942TG1991PLC013564. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Hindustan Bio Sciences is listed on BSE with code 532041.
Hindustan Bio Sciences has 5 court cases on record: 1 filed by the company and 4 filed against it. Most are in the high courts.
Hindustan Bio Sciences was incorporated on 16 December 1991, making it 35+ years old. It is registered with the Registrar of Companies, Hyderabad.
Hindustan Bio Sciences has 78 deals on record (78 market trades); the latest was in October 2025.
Nagi Reddy Bodeddula was appointed as Director on 30 Sep 2024. Pratheek Reddy Gorrela was appointed as Director on 30 Sep 2024. Ramachandra Raju Kalidindi ceased to be Director on 30 Sep 2024. Hindustan Bio Sciences has 20 board changes on record in total.